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Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter occurs in about 40% of breast tumours and has been
correlated with reduced APC protein levels. To what extent epigenetic alterations of the APC gene may differ according to specific
breast cancer phenotypes, remains to be elucidated. Our aim was to explore the role of APC methylation in the inflammatory breast
cancer (IBC) phenotype. The status of APC gene promoter hypermethylation was investigated in DNA from normal breast tissues,
IBC and non-IBC by both conventional and real-time quantitative methylation-specific PCR (MSP). APC methylation levels were
compared with APC mRNA and protein levels. Hypermethylation of the APC gene promoter was present in 71% of IBC samples
(n¼21) and 43% of non-IBC samples (n¼30) by conventional MSP (P¼0.047). The APC gene also showed an increased frequency
of high methylation levels in IBC (in 74% of cases, n¼19) vs non-IBC (in 46% of cases, n¼35) using a qMSP assay (P¼0.048). We
observed no significant association between APC methylation levels by qMSP and APC mRNA or protein expression levels. In
conclusion, for the first time, we report the association of aberrant methylation of the APC gene promoter with the IBC phenotype,
which might be of biological and clinical importance.
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The adenomatous polyposis coli (APC) gene, mapped to chromo-
some 5q21 (Kinzler et al, 1991), plays a prominent role in the
development of colorectal cancer, both in the autosomal dominant
inherited familial APC syndrome (Bodmer et al, 1987; Groden et al,
1991; Joslyn et al, 1991; Kinzler et al, 1991; Nishisho et al, 1991)
and in sporadic colorectal cancer (Fearon and Vogelstein, 1990;
Miyoshi et al, 1992; Powell et al, 1992). An impaired function of
APC, most often attributable to mutations within the coding
sequence of the gene, leads to a lack of degradation and nuclear
accumulation of b-catenin, which acts as a transcriptional
activator, causing loss of cell growth control (Sparks et al, 1998).
Moreover, APC functions in pathways counteracting metastasis by
mediating intercellular adhesion and stabilising the cytoskeleton
(Fearnhead et al, 2001).
Similar to findings in colorectal cancers, it has been suggested
that disruption of the APC/b-catenin pathway may be involved in
breast cancer. Loss of APC expression and upregulation of
b-catenin have been described in human breast cancer and breast
cancer cells (Ho et al, 1999; Jonsson et al, 2000; Schlosshauer et al,
2000). Somatic APC mutations are reported in only a minority of
breast cancers (Furuuchi et al, 2000), despite high rates of allelic
loss at chromosome locus 5q21 (Thompson et al, 1993; Medeiros
et al, 1994). Nevertheless, epigenetic inactivation of APC due to
DNA methylation is frequently present in both breast cancer cell
lines and breast cancer tissue. In most cultured breast cancer cells,
there is a complete concordance between APC promoter methyla-
tion and silencing of its transcript (Virmani et al, 2001). Cellular
APC expression can be restored after demethylation with 5-aza-20-
deoxycytidine treatment. APC promoter methylation also occurs
in a significant number of primary breast tumours (ranging from
28 to 53% of cases, depending on the applied technology) (Jin et al,
2001; Virmani et al, 2001; Liu et al, 2007). The frequency of APC
methylation in primary breast tumours increases with tumour
stage and size (Virmani et al, 2001; Roa et al, 2004; Chen et al,
2007; Liu et al, 2007). Moreover, hypermethylation of APC can be
detected in breast aspirate fluid DNA (Lee et al, 2004) and serum
DNA from patients with pre-invasive and early-stage breast cancer
(Dulaimi et al, 2004a). DNA methylation of APC in serum of early
breast cancer patients who had not undergone adjuvant systemic
treatment appeared to be an independent prognostic marker for
overall survival (Muller et al, 2003, 2004). These findings indicate a
potential for the use of this epigenetic marker, alone or in
combination with other markers, both for early detection of breast
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scancer and for clinical, routine risk assessment in patients with
breast cancer.
Epigenetic inactivation due to hypermethylation is well estab-
lished for APC in breast carcinoma but as yet, few studies have
addressed whether epigenetic alterations of the APC gene might
characterise specific breast cancer phenotypes. Because of their
similar treatment, inflammatory breast cancer (IBC) has been
rarely studied separately from other forms of locally advanced
breast cancer in the past, despite differences in age-specific
incidence rates, clinical presentation, histology, hormone receptor
status and, finally, prognosis (Lerebours et al, 2005). Recent
reports, however, have revealed a unique molecular profile of IBC
(Bertucci et al, 2004; Van Laere et al, 2005, 2007), shedding light on
its unique ability to rapidly invade and metastasise. This has led us
to consider the possibility of a specific methylation pattern for this
breast cancer phenotype. Notably, biological processes that are
altered in IBC include cell motility, cell adhesion, regulation of the
cell cycle, invasion and angiogenesis (see reference Dirix et al, 2006
and references therein). An important role for epigenetic silencing
of APC in IBC might be expected based on previous studies from
our group that showed low expression of this gene in IBC
compared to non-IBC (unpublished data).
The aim of our study was to explore the role of APC methylation
in the IBC phenotype. We therefore investigated independently the
methylation status of the APC gene promoter in DNA from
inflammatory and non-inflammatory breast tumours, as well as
from non-neoplastic breast tissues by using both a conventional
methylation-specific PCR (MSP) method and a quantitative real-
time MSP (qMSP) approach. Furthermore, we compared APC
methylation levels obtained by qMSP with APC mRNA and protein
levels.
MATERIALS AND METHODS
Patients and sample collection
A total of 105 snap-frozen or paraffin-embedded human breast
tumour samples was retrieved from the tissue archive of the
General Hospital Sint-Augustinus, Wilrijk, Belgium. Two different
data sets were used in this study (see Table 1). Conventional MSP
was performed on 51 paraffin-embedded tumour samples, of
which 21 were IBC and 30 were non-IBC. Patient age at diagnosis
ranged from 49 to 78 years (mean, 63 years) for non-IBC patients
and from 31 to 82 years (mean, 60 years) for IBC patients. In
addition, 27 non-neoplastic breast tissues from women who had
breast reductive surgery were used. These patient ages ranged from
24 to 62 years (mean, 42 years). qMSP was performed on 54
snap-frozen tumour samples, of which 19 were IBC and 35 were
non-IBC. Patient age at diagnosis ranged from 31 to 89 years
(mean, 59 years) for non-IBC patients and from 45 to 74 years
(mean, 60 years) for IBC patients. In addition, 15 matched normal
breast tissues adjacent to a breast tumour and 9 non-neoplastic
breast tissues from women who had breast reductive surgery were
used in this experiment.
All cases were randomly selected. IBC was diagnosed according
to the criteria mentioned in the AJCC (American Joint Committee
on Cancer)-TNM staging system (Singletary et al, 2002). All
patients with IBC showed diffuse enlargement of the involved
breast of sudden onset. There was erythema and oedema of the
skin involving more than one-third of the breast. The presence of
dermal lymphatic invasion as an isolated observation was not
sufficient for the diagnosis of IBC and was not necessary for the
diagnosis either. Relevant clinical data at diagnosis, such as age,
clinical stage (AJCC TNM staging system), histological grade
(Nottingham modification of the Bloom and Richardson histolo-
gical grading system (Bloom and Richardson, 1957; Elston, 1984))
and hormone receptor status were obtained from medical records.
Each patient gave a written informed consent. All protocols were
reviewed and approved by the Ethical Committee of the General
Hospital Sint-Augustinus.
Conventional nested MSP
Paraffin sections (10mm in thickness) from the primary breast
tumours were cut on a clean blade. Paraffin ribbons were then
mounted on membrane-covered metal frame slides (MMI,
Glattbrug, Switzerland) and dried overnight. Tissue sections were
deparaffinised in xylene and rehydrated through a graded alcohol
series to nuclease-free water. Tissue sections were stained with the
HistoGene staining solution (Arcturus Engineering Inc., Mountain
View, CA, USA), specifically designed to preserve intact nucleic
acids from captured cell populations. The SLmCut system (MMI)
with a solid-state UV laser was used for microdissection of tumour
epithelial cells (average tissue area of 8mm
2).
DNA extractions from microdissected tumour epithelial cells
were performed using the QIAamp DNA Micro Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s protocols.
Sodium bisulphite conversion of DNA samples was carried out
using reagents provided in the EZ DNA Methylation Kit (Zymo
Research, Orange, CA, USA). Five hundred ng of DNA were
treated with sodium bisulphite following the manufacturer’s
recommendations.
Bisulphite-treated DNA was used as a template for a conven-
tional nested MSP to determine the presence or absence of
methylation of the promoter region of APC. Template ampli-
fication by a nested MSP was done essentially as described earlier
(House et al, 2003). Step one primers flanked the CpG-rich
promoter region of APC. PCR products of step one were diluted
1:1000 and subjected to the second step of MSP that incorporated
a set of primers (labelled as unmethylated (U) or methylated (M))
that were designed to recognise sodium bisulphite-induced
modifications of unmethylated cytosines. The primer sequences
are listed elsewhere (House et al, 2003). Both steps of the nested
MSP utilised a 25ml reaction volume, 0.5ml of Jump Start Red Taq
DNA polymerase (Sigma, St Louis, MO, USA) and 4ml of DNA
template. The thermal profile for step one of the nested MSP was as
follows: 3min at 951C, then 35 repetitive cycles of denaturation
(951C 30s), annealing (561C 30s) and extension (721C 30s),
followed by a final 4min extension at 721C. Step two of the nested
MSP was performed in a similar fashion with a few adjustments to
the annealing temperature (601C) to allow for optimal template
discrimination, and to the PCR cycle number (25). DNA isolated
from normal peripheral lymphocytes from healthy individuals
served as a negative methylation control. In vitro methylated DNA
was used as the positive methylation control. Each PCR product
(10ml) was loaded onto a 1.0% agarose gel, stained with GelStar
nucleic acid stain solution (Cambrex Charles City, IA, USA) and
directly visualised under UV illumination.
Quantitative real-time MSP
DNA extractions from snap-frozen tissue specimens were
performed using the QIAamp DNA Micro Kit (Qiagen, Valencia,
CA, USA) according to the manufacturer’s protocols. Sodium
bisulphite conversion of DNA samples was carried out using the
EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA).
Two mg of DNA were treated with sodium bisulphite following the
manufacturer’s recommendations.
The real-time PCR-based quantification of APC methylation
levels was done essentially as described earlier (Eads et al, 2000).
Two sets of primers and probes, designed specifically for sodium
bisulphite-converted DNA, were used: a methylated set for APC
and a reference set, b-actin (ACTB), to normalise for input DNA.
The primers and probes used for APC and ACTB are listed
elsewhere (Eads et al, 2000; Usadel et al, 2002). Fluorogenic PCRs
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7900 Sequence Detector (Applied Biosystems, Foster City, CA,
USA). PCR was carried out in separate wells for each primer/probe
set, and each sample was run in duplicate. The final reaction
mixture consisted of 600nmoll
 1 of each primer (Applied
Biosystems), 200nmoll
 1 of probe (Applied Biosystems) and
12.5ml of Universal Master Mix (Applied Biosystems). Five ml
of bisulphite-converted genomic DNA (250ng) was used in
each real-time MSP reaction. Thermal cycling was initiated with
a first denaturation step of 951C for 10min. The thermal profile for
the PCR was 951C for 15s and 601C for 1min. Data obtained
during 50 cycles of amplification were analysed. Each plate
included water blanks, a positive and a negative control. DNA
isolated from normal peripheral lymphocytes from healthy
individuals served as a negative methylation control. In vitro
methylated human DNA (Zymo Research) was used as the positive
methylation control.
The ratio between the values obtained in the two TaqMan
analyses was used as a measure for the degree of methylation of
APC. The percentage of fully methylated molecules at the APC
locus was calculated by dividing the APC/ACTB ratio of a sample
by the APC/ACTB ratio of fully methylated human DNA and
multiplying by 100. We use the abbreviation PMR (Percentage of
Methylated Reference) to indicate this measurement.
Quantitative real-time RT–PCR
APC methylation levels by qMSP were compared to APC mRNA
expression levels by qRT–PCR in 52 frozen breast tumour biopsies
(of which 19 were IBC and 33 were non-IBC). For two cases, tissue
was not in sufficient quantity for performing both analyses.
RNA isolation and expression analyses were performed as
described earlier (Van der Auwera et al, 2004). Briefly, total RNA
was isolated with the RNeasy Mini RNA isolation kit (Qiagen,
Valencia, CA, USA) and cDNA was synthesised from 1mg of total
RNA with the cDNA Archive kit (Applied Biosystems). Primers
and probes were purchased from Applied Biosystems assay-on-
demand. All samples were run on a 7900HT Fast Real-time PCR
Detector (Applied Biosystems) in duplicate. Quantitative RT–PCR
was performed in a reaction volume of 25ml including 10mlo f
cDNA. We averaged the expression of ACTB and 18SrRNA as
internal reference genes to normalise input cDNA. The 2 DDCt
method was used to compute relative expression values (Livak and
Schmittgen, 2001).
Immunohistochemical staining of TMA
The tissue microarray (TMA) used in this study was described
earlier (Van Laere et al, 2007). Briefly, formalin-fixed, paraffin-
embedded tissue blocks containing breast cancer were retrieved
from the archives of the General Hospital St-Augustinus. Areas of
invasive breast carcinoma were identified on corresponding
haematoxylin and eosin-stained slides, and the tissue blocks were
cored and transferred to a recipient ‘master’ block using a Tissue
Microarrayer (Beecher Instruments, Silver Spring, MD, USA). A
total cohort of 76 cases of breast cancer was divided between two
slides. Four cores were arrayed for each specimen.
TMA slides (4mm in thickness) were deparaffinised, hydrated
and subjected to antigen retrieval by heating slides in 10mM citrate
buffer (sodium citrate, pH 6.0) at 981C for 30min, followed by a
30min cool-down and rinsing in wash buffer. The sections were
incubated in 3% H2O2 for 10min to inhibit endogenous
peroxidase. The sections were subsequently incubated at room
temperature with antibodies against the C-terminal region of the
APC protein (C-20, 1:100, 60min; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), after which sections were stained using the
DAKO EnVision detection system (Dako, Glo ¨strup, Denmark).
Sections were developed using 3,30-diaminobenzidine for 10min,
counterstained with haematoxylin and mounted with Aquatex
medium (Merck, Darmstadt, Germany).
Stained slides were then analysed for APC expression. Tumours
were graded into two categories based on staining pattern: those
showing loss of expression and those with expression.
Table 1 Tumour characteristics
Conventional MSP Quantitative real-time MSP
Clinicopathological factors IBC (N¼21) Non-IBC (N¼30) IBC (N¼19) Non-IBC (N¼35)
Patients’ ages (years)
Mean 62.7 59.8 60.0 58.6
Range 49–78 31–82 45–74 31–89
Tumour stage
I0 7 0 1 0
II 0 13 0 15
III 11 8 13 7
IV 10 2 6 3
Histological type
Invasive ductal 21 29 16 30
Invasive lobular 0 1 3 5
Histological grade
Well 0 5 0 11
Moderate 8 18 9 17
Poor 13 7 9 7
Oestrogen receptor
Positive 10 18 11 30
Negative 11 12 8 5
Progesterone receptor
Positive 7 14 4 21
Negative 14 16 15 14
Hypermethylation of APC in inflammatory breast cancer
I Van der Auwera et al
1737
British Journal of Cancer (2008) 99(10), 1735–1742 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sStatistical analysis
APC gene methylation was analysed in two ways: as a continuous
variable and as a dichotomous variable (i.e., high or low, using the
median PMR value as a threshold). As a continuous variable, the
association of APC methylation with type of tumour (inflammatory
vs non-inflammatory) and with the different groups of clinical
variables was summarised using the Mann–Whitney and
Kruskal–Wallis non-parametric tests, according to the number
of categories. To summarise the associations between APC
methylation (coded as high or low) and tumour type or other
clinical variables we used the w
2 statistics. The Fisher’s Exact Test
was used when one cell had an expected count of less than 5. The
level of significance was set to Po0.05. All analyses were carried
out using SPSS version 11.0 (SPSS, Chicago, IL, USA).
RESULTS
APC methylation analysis by conventional MSP
The APC promoter region was analysed for presence or absence of
methylation in formalin-fixed and paraffin-embedded tissue sam-
ples of invasive breast cancer (including 30 cases of non-IBC and 21
cases of IBC) and of non-neoplastic breast tissue from unaffected
women (n¼27) for control purposes. Hypermethylation of the APC
gene promoter was observed in 28 of 51 (55%) breast tumours. A
low frequency of methylation (11%) was also present in non-
neoplastic breast tissues (obtained from reduction mammoplasty
specimens, n¼27). When we compared methylation frequencies of
breast tumours, a higher frequency of APC promoter methylation
was found in IBC (71%) when compared to non-IBC (43%)
(P¼0.047; w
2). Representative examples of the MSP products of
bisulphite-treated samples using primers for specific unmethylated
and methylated sequences are shown in Figure 1.
It was reported earlier that gene methylation increases with age
(Issa, 2000). Therefore, the high incidence of aberrant methylation
in breast carcinoma specimens compared with normal breast
tissue could be, at least in part, because of the older age of the
average patient with breast cancer. However, a statistical analysis
revealed no correlation between patient age and frequency of
hypermethylation in our series of normal breast specimens
(n¼27) (P¼0.583; Mann–Whitney test). We compared breast
carcinoma specimens from patients 50 years old or younger
vs specimens from patients older than 50 years and again, we did
not observe a significant difference in frequency of APC
methylation between these two patient groups (P¼0.349; w
2).
There was a significant correlation of APC promoter hyper-
methylation with the histological grade of the tumour
(P¼0.034; w
2) and with tumour stage (P¼0.026; w
2) in our series
of breast carcinomas (n¼51). No associations were found with
other tumour characteristics (tumour size, presence of axillary
metastasis, expression of ER and PR and HER2 or p53 status).
APC methylation analysis by quantitative real-time MSP
A real-time MSP assay was used to quantify the relative number of
methylated alleles in frozen breast tumour specimens from 35
patients with non-IBC and 19 patients with IBC. In addition, the
methylation analysis was performed on DNA from matched
non-neoplastic breast tissues from cancer patients (n¼15) and
from non-neoplastic breast tissues from unaffected women (n¼9).
APC promoter methylation was detectable in 53 of 54 (98%) of
breast carcinoma samples. In seven of nine (78%) non-neoplastic
breast tissues from unaffected women, APC promoter methylation
could be detected, albeit at a very low level. The median PMR value
was 0.03 (range, 0.00–0.18) for non-neoplastic breast tissue
(n¼9), 0.68 (range, 0.00–94.31) for non-IBC (n¼35) and 9.78
(range, 0.01–68.04) for IBC (n¼19) (Figure 2). Comparison
between non-neoplastic (n¼9) and cancer tissue (n¼54) revealed
statistically significant results (P¼0.006; Mann–Whitney test).
Comparison of PMR values between IBC and non-IBC revealed no
significant results. However, when cases were coded based on
methylation levels (using as a threshold the median PMR value),
the frequency of IBC samples with a high APC methylation status
(74%) was significantly increased when compared to non-IBC
(46%) (P¼0.048; w
2).
Furthermore, we compared APC methylation levels in matched
normal appearing breast tissue and primary breast tumour.
T11 T12 T13 T14 T15 T16 T17 T18 T19 N8 N9 N10
UM UM UM UM UM UM UM UM UM UM UM UM
Figure 1 Results of conventional MSP in human breast cancer samples and normal breast tissues. The presence of a PCR product in lanes marked M
indicates methylated APC promoter, whereas a product in lanes marked U indicates unmethylated promoter. IBC cases T11, T13 and T18, non-IBC case T16
and normal breast tissues N8 and N9 have both methylated and unmethylated promoters, whereas IBC case T17, non-IBC cases T12, T14, T15 and T19
and normal breast tissue N10 show only unmethylated promoters.
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Figure 2 Promoter methylation levels of APC in non-neoplastic breast
tissue (n¼9), matched normal breast tissue adjacent to a breast tumour
(n¼15) and biopsies from patients with non-IBC (n¼35) and patients
with IBC (n¼19). Box plots show median, upper and lower quartiles.
Median PMR values were 0.03 (range, 0–0.18) for non-neoplastic breast
tissue, 0.29 (range, 0–26.35) for matched normal breast tissue adjacent to
a breast tumour, 0.68 (range, 0.00–94.31) for non-IBC and 9.78 (range,
0.01–68.04) for IBC.
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normal and cancerous tissue was available for analysis), we did
observe a trend towards a correlation between PMR values in
normal appearing adjacent tissue and carcinoma cells (r¼0.502,
P¼0.057) (Figure 3). PMR values for APC were significantly
elevated in tumour compared with matched normal breast tissue
(P¼0.022; Wilcoxon signed-rank test). The median level of APC
methylation was 3.27 (range, 0.01–94.31) in tumour compared
with 0.29 (range, 0–26.35) in matched normal tissue.
Overall, there were no statistical differences between PMR values
in tumour tissue and clinicopathological factors (tumour size
and stage, presence of axillary metastasis, histological grade,
expression of ERs and HER2 or p53 status), with the exception of
the expression of PR, for which a statistical trend toward higher
methylation levels in PR-negative breast tumours was observed
(P¼0.075; Mann–Whitney). No association was found between
PMR values in tumour tissue and patient age.
Concordance of conventional MSP and quantitative
real-time MSP
As a validation, the results of qMSP were compared with those
obtained by conventional MSP in 18 patient samples (including
nine cases of non-IBC and nine cases of IBC). There was a
substantial agreement between results obtained by quantitative
real-time MSP and those obtained by conventional MSP (k¼0.658,
P¼0.005). Nine of 10 cases (90%) negative for APC hyper-
methylation by conventional MSP were also negative by quantitative
real-time MSP whereas six of eight cases (75%) positive for APC
hypermethylation by conventional MSP were also positive by
quantitative real-time MSP.
Correlation of APC methylation levels by qMSP and APC
mRNA expression
We compared promoter methylation status of APC defined by
qMSP to loss of mRNA expression assessed by qRT–PCR in 52 of
54 (96%) breast tumour samples (including 19 IBC and 34 non-
IBC) (Figure 4). In two breast cancer cases, frozen tissue was not
sufficient in quantity for performing both analyses. The expression
of APC appeared to be unrelated to the associated levels of APC
methylation in breast cancer samples (n¼52). The median APC
mRNA expression level was 58.22 (range, 29.84–82.67) in samples
with a high methylation status and 54.12 (range, 20.72–105.25)
in samples with a low methylation status (P¼0.600,
Mann–Whitney).
Correlation of APC methylation levels by qMSP and APC
protein expression
To determine whether APC promoter hypermethylation affects protein
expression in breast tumours, we assessed the association between
APC methylation levels by qMSP and loss of APC protein expression
by immunohistochemistry in 34 of 54 (63%) breast tumours
(including 22 cases of non-IBC and 12 cases of IBC) (Figure 4).
Intensive cytoplasmic expression of the APC protein was found in
28 of 34 cases (82.3%) in our series, whereas the other six cases
(17.6%) showed loss of the APC protein (Figure 5). The APC protein
expression in breast cancer was independent of the APC methylation
level. Of the 10 breast cancers with low APC methylation status by
qMSP, eight (80%) expressed APC protein. Of the 24 cases of invasive
breast cancer with high APC methylation status by qMSP, loss of APC
protein was seen in four (16.7%).
DISCUSSION
Epigenetic CpG-island hypermethylation of the promoter region
has been proposed as an alternative way to inactivate the APC
tumour suppressor gene. It has been shown that APC gene
hypermethylation can be detected in ductal carcinoma in situ,
lobular carcinoma in situ, and invasive ductal and lobular tumours
of all pathological grades and stages, which indicates that
hypermethylation of APC can be a relatively early event in breast
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Figure 3 The methylation levels were compared between matched
benign and breast cancer tissues from 15 patients with breast cancer.
y-axis, the percentages of fully methylated reference in each patient sample
as obtained by qMSP. x-axis, benign (normal) or breast cancer (cancerous)
tissues.
0
20
40
60
80
100
120
IHC
0
10
20
30
40
50
60
70
80
90
100
A
P
C
 
m
e
t
h
y
l
a
t
i
o
n
 
l
e
v
e
l
(
P
M
R
 
v
a
l
u
e
s
)
A
P
C
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
 
b
y
 
q
R
T
–
P
C
R
Figure 4 Comparison of APC promoter methylation, APC mRNA
expression and APC protein expression in 54 breast tumours. (Upper)
Methylation status of the APC locus as determined by qMSP. (Lower) APC
mRNA expression levels measured by real-time quantitative RT–PCR
(n¼52). APC protein status is indicated by circles located between the
two charts (n¼34). An open circle indicates APC positivity, whereas a
black circle denotes APC negativity, as determined by immuno-
histochemistry (IHC).
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stumorigenesis (Dulaimi et al, 2004a). It remains to be determined
to what extent epigenetic alterations of the APC gene might
characterise specific breast cancer phenotypes. This study
represents the first comprehensive comparison of the frequencies
of APC gene promoter hypermethylation in the inflammatory and
non-inflammatory breast cancer phenotype. For this purpose, the
APC gene was analysed independently by two different techniques:
a conventional MSP and a quantitative real-time MSP.
We performed laser capture microdissection of archival
histological sections to collect relatively pure, or at least
considerably enriched, populations of tumour epithelial cells.
Because of the inherent difficulties (i.e., DNA degradation as a
result of the formalin fixation and the typical small sample size) of
assaying for methylation in DNA recovered from microdissected
tissues, we used the nested variant of the classical MSP to analyse
these samples. This technique, originally developed by Palmisano
et al (2000), incorporates a two-stage PCR approach that allows a
more sensitive (one methylated allele in 450000 unmethylated
alleles) detection of methylation in clinical samples harbouring
small amounts of poor quality DNA. The frequency of APC
methylation in our series of primary breast cancers was consistent
with that recently reported by others (Jin et al, 2001; Virmani et al,
2001; Dulaimi et al, 2004b; Liu et al, 2007). Notably, specimens
from patients with IBC had the highest frequency of methylation.
Although the P-value was only just significant, IBC samples
showed 1.6 times more APC hypermethylation than non-IBC
samples. APC methylation was associated with histological grade
and tumour stage but this should be confirmed on a larger data set.
The strictly qualitative detection of methylation by the
conventional MSP is hampered by some shortcomings (Ogino
et al, 2006): (a) conventional MSP cannot reliably distinguish low
levels of methylation from high levels of methylation; (b) the
frequency of hypermethylation might be overestimated
(Aggerholm and Hokland, 2000; Brakensiek et al, 2004); and
(c) assay performance characteristics are difficult to assess. To
validate the acquired conventional MSP data and, also, to obtain
additional information on the fraction of methylated alleles in IBC
and non-IBC, we combined our conventional MSP results with
those obtained by a quantitative real-time MSP assay. This assay
was performed separately on DNA samples purified from frozen
breast tumour biopsies collected at the time of surgery. All samples
were evaluated by a pathologist to assess the presence of malignant
cells. Although for only 18 samples (nine IBC and nine non-IBC),
snap-frozen and formalin-fixed and paraffin-embedded biopsies
were available in parallel, the quantitative real-time MSP results
corroborated the observations by conventional MSP. PMR values
were not significantly different in IBC and non-IBC specimens
(which might reflect variation in the tumour cell content of
biopsies). However, high APC methylation levels were 1.6 times
more frequently present in IBC specimens than in non-IBC
specimens, which was just statistically significant.
The methylation levels of APC in samples from non-neoplastic
tissue adjacent to a breast tumour correlated with that observed in
samples of the corresponding tumour tissue (trend for statistical
significance). Notably, APC methylation levels in ‘normal’ tissue
from cancer patients were significantly higher than in breast tissue
from unaffected women and in some cases values as high as those
observed in breast tumour tissue were measured. In a recent
comprehensive study of methylation of RASSF1A promoter in
breast tissue samples, it was uncovered that primary tumours had
significantly higher promoter methylation than control reduction
mammoplasty tissue, with adjacent normal samples having
intermediate levels (Yan et al, 2006). Interestingly, global profiling
of DNA methylation revealed more methylated genes in normal
adjacent samples than in normal donor control samples. There are
several possible explanations for this observation. The intermedi-
ate levels of methylation might reflect the infiltration of neoplastic
cells in histologically ‘normal’ surrounding breast tissue. Alter-
natively, the hypermethylation of genes in samples from normal
tissue adjacent to a breast tumour could be explained by field
cancerisation. This concept was originally proposed by Slaughter
et al (1953) to explain the development of multiple primary
tumours and locally recurrent cancer (Slaughter et al, 1953).
Previous studies have confirmed that genetic abnormalities exist in
histologically normal breast tissues immediately adjacent to
invasive cancers (Deng et al, 1996). Now, it has also been
suggested that the primary tumour might serve as an epicentre
from which methylation density progressively diffuses outwards to
surrounding tissues (Yan et al, 2006).
We found no significant difference in APC mRNA and protein
levels among tissues with low or high APC methylation status.
Possible explanations for these results are: (i) samples with APC
promoter methylation may have only one allele affected, allowing
expression from the unaltered allele (Esteller et al, 2000); (ii) gene
silencing is not a single event, but instead a series of events that
begin with a marked drop in transcription and ends with its
complete cessation (Turker, 2002); (iii) APC methylation patterns
among the tumour cells that constitute a given sample might be
heterogeneous and (iv) APC expression might be inactivated by
gene mutations or allelic losses and not by methylation of CpG
sites in the promoter region.
To conclude, we have shown that aberrant methylation of the
APC gene promoter characterises the IBC phenotype. It should be
emphasised that more investigation is required to determine to
what extent the epigenetic inactivation of APC affects the biological
behaviour of these tumours. Our study was limited not only by the
small sample size, but also by the use of a candidate gene approach
that was based on the observation of low gene expression. The
analysis of more IBC cases and the consideration of additional
genes, which is facilitated by several recently described techniques,
such as methylation-sensitive arbitrarily primed PCR, restriction
landmark genomic sequencing and CpG-island microarrays (see
AB
Figure 5 APC expression in human breast cancer. (A) Breast cancer with normal APC expression. (B) Breast cancer with loss of APC protein expression.
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sreference (Ushijima, 2005) and references therein), could present a
great opportunity for enriching our knowledge of IBC biology.
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